Kurs
-1,70%
Likviditet
1,83 MNOK
Kalender
Tid* | ||
2025-02-13 | 07:30 | Bokslutskommuniké 2024 |
2025-01-09 | N/A | Extra Bolagsstämma 2025 |
2024-11-06 | - | Kvartalsrapport 2024-Q3 |
2024-08-21 | - | Kvartalsrapport 2024-Q2 |
2024-05-07 | - | Kvartalsrapport 2024-Q1 |
2024-04-25 | - | X-dag ordinarie utdelning ULTI 0.00 NOK |
2024-04-24 | - | Årsstämma |
2024-02-14 | - | Bokslutskommuniké 2023 |
2023-11-08 | - | Kvartalsrapport 2023-Q3 |
2023-08-22 | - | Kvartalsrapport 2023-Q2 |
2023-05-10 | - | Kvartalsrapport 2023-Q1 |
2023-04-21 | - | X-dag ordinarie utdelning ULTI 0.00 NOK |
2023-04-20 | - | Årsstämma |
2023-02-16 | - | Bokslutskommuniké 2022 |
2022-11-10 | - | Kvartalsrapport 2022-Q3 |
2022-08-19 | - | Kvartalsrapport 2022-Q2 |
2022-05-12 | - | Kvartalsrapport 2022-Q1 |
2022-04-21 | - | X-dag ordinarie utdelning ULTI 0.00 NOK |
2022-04-20 | - | Årsstämma |
2022-02-17 | - | Bokslutskommuniké 2021 |
2021-11-11 | - | Kvartalsrapport 2021-Q3 |
2021-08-20 | - | Kvartalsrapport 2021-Q2 |
2021-05-11 | - | Kvartalsrapport 2021-Q1 |
2021-04-22 | - | X-dag ordinarie utdelning ULTI 0.00 NOK |
2021-04-21 | - | Årsstämma |
2021-02-17 | - | Bokslutskommuniké 2020 |
2020-11-12 | - | Kvartalsrapport 2020-Q3 |
2020-11-11 | - | Extra Bolagsstämma 2020 |
2020-08-21 | - | Kvartalsrapport 2020-Q2 |
2020-05-14 | - | Kvartalsrapport 2020-Q1 |
2020-04-16 | - | X-dag ordinarie utdelning ULTI 0.00 NOK |
2020-04-15 | - | Årsstämma |
2020-02-14 | - | Bokslutskommuniké 2019 |
2019-11-14 | - | Kvartalsrapport 2019-Q3 |
2019-08-21 | - | Kvartalsrapport 2019-Q2 |
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Bioteknik |
Oslo, 10 February 2022: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, invites to a webcast presentation of its fourth quarter 2021 results on Thursday 17 February 2022.
The presentation can be followed as a live webcast accessed through a link on www.ultimovacs.com at 09:00 CET on Thursday 17 February 2022. The webcast presentation will be available on the Ultimovacs website, and it will be possible to post questions during the presentation through the webcast.
The report and presentation will be available on the company website from 08:00 CET the same day.
For further information, please see www.ultimovacs.com or contact:
Carlos de Sousa, CEO
Email: carlos.desousa@ultimovacs.com
Phone: +47 908 92507
Hans Vassgård Eid, CFO
Email: hans.eid@ultimovacs.com
Phone: +47 482 48632
Anne Worsøe, Head of IR & Communication
Email: anne.worsoe@ultimovacs.com
Phone: +47 906 86815
Mary-Ann Chang, LifeSci Advisors
Email: mchang@lifesciadvisors.com
Phone: +44 7483 284 853